Akero Therapeutics Press Release
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip
Akero Therapeutics (AKRO)
This content is for paid subscribers.
Today’s Highlights
October 10, 2023
